results from the operation. Although the most recent
AHA guidelines do not classify CEA as a high-risk surgical procedure mandating ␤-blockade, they do indicate
that all patients with known CAD should receive

Antihypertensive, ␤-blocker, and lipid-lowering therapy should be initiated in patients undergoing CAS according to the same recommendations for CEA. Patients should
be started on dual antiplatelet therapy with aspirin (325
mg